> For the complete documentation index, see [llms.txt](https://miradao.gitbook.io/miradao-whitepaper/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://miradao.gitbook.io/miradao-whitepaper/roadmap/usdmira-roadmap.md).

# $MIRA Roadmap

### **Phase 1: Foundation & Launch**

**Infrastructure**

Q1

* ✅ Official Website
* ✅ Whitepaper and Roadmap
* ✅ Social channels (Twitter, Telegram) established.
* DAO Setup
* First POAP Claim for Hankinson Donation (along with infrastructure)

**Direct Support**

1. Donated $1,000,000 to rare disease research to the Hankinson Lab at [@ChildrensColo](https://x.com/ChildrensColo):[https://x.com/blader/status/1873156136553332859…](https://x.com/blader/status/1873156136553332859%E2%80%A6)
2. Donated $100K to [@jsncurry](https://x.com/jsncurry) and [$JACK](https://x.com/search?q=%24JACK\&src=cashtag_click) for rare disease research and treatment:[https://x.com/jsncurry/status/1873517863967080459…](https://x.com/jsncurry/status/1873517863967080459%E2%80%A6)
3. Donated $100K to [@gentherapyben](https://x.com/gentherapyben) and [$BEN](https://x.com/search?q=%24BEN\&src=cashtag_click) for rare disease treatment:

[https://x.com/gentherapyben/status/1873390555734089734…](https://x.com/gentherapyben/status/1873390555734089734%E2%80%A6)

**Impact Marketing**

Partner with established charities to host events, awareness campaigns, or co-branded merchandise—**not** to raise funds through $MIRA sales, but to generate **public attention** for their cause.

{% embed url="<https://x.com/TheGivingBlock/status/1873147817260401036>" %}

{% embed url="<https://x.com/jsncurry/status/1873517863967080459>" %}

### **Phase 2: Eosystem Growth & Launchpad**

**Infrastructure**

**Q2**

* Initial beta test of the MIRA AI agent, an autonomous AI agent designed to evaluate new launchpad proposals, answer questions about raw diseases, and summarize frontier research progress for new therapeutics.
* Additional POAP claims as new donations are made.

**Q3**

* Build and deploy **MIRA Launchpad**, allowing new projects to fundraise using $MIRA.
* Provide user-friendly tools for token offerings and liquidity management.
* **Outcome**: Expand $MIRA’s utility by enabling external projects to leverage its liquidity and community.

**Impact Marketing**

**Q2-Q4**

* Partner with **influencers**, philanthropic leaders, and medical professionals to broaden reach.
* **Continued Social Media Campaigns**: Focus on telling patient success stories and research breakthroughs funded by $MIRA.

### **Phase 3: Global Adoption & Maturity**

**Cross-Chain Integrations & Bridges**

* **Q1 (Year 2)**:
  * Evaluate bridging solutions (Wormhole, Multichain) to bring $MIRA to other ecosystems (Ethereum, Polygon, etc.).
  * Maintain liquidity pools on multiple chains, if feasible.
* **Outcome**: Expand user base and philanthropic reach across various blockchain networks.

**Strategic Nonprofit Alliances**

* **Ongoing**:
  * Collaborate with major international children’s hospitals, university research centers, and philanthropic institutions.
  * Showcase monthly impact reports to donors, community, and the media.
* **Outcome**: **Strong brand recognition** as the leading “charity crypto,” with a consistent track record of funding groundbreaking research.

**Institutional Partnerships**

* **Year 2**:
  * Encourage philanthropic trusts, corporate CSR programs, and endowments to hold $MIRA.
  * Offer specialized consulting on **crypto donations** and **tax-efficient giving**.
* **Outcome**: Broader adoption, diversification of token holders, and more robust donation streams.